4Friedman SL. Liver fibrosis -- from bench to bedside. J Hepatol2003; 38 Suppl 1:S38-S53.
5Friedman SL. Seminars in medicine of the Beth Israel Hospital, Boston. The cellular basis of hepatic fibrosis. Mechanisms and treatment strategies. N Engl J Med 1993; 328:1828-1835.
6Parsons CJ, Bradford BU, Pan CQ, Cheung E, Schauer M, Knorr A, Krebs B, Kraft S, Zahn S, Brocks B, Feirt N, Mei B, Cho MS, Ramamoorthi R, Roldan G, Ng P, Lum P, Hirth-Dietrich C,Tomkinson A, Brenner DA. Antifibrotic effects of a tissue inhibitor of metalloproteinase-1 antibody on established liver fibrosis in rats. Hepatology 2004; 40: 1106-1115.
7Lewindon PJ, Pereira TN, Hoskins AC, Bridle KR, Williamson RM, Shepherd RW, Ramm GA. The role of hepatic stellate cells and transforming growth factor-beta(I) in cystic fibrosis liver disease. Am J Patho12002; 160:1705-1715.
8Iredale JP. Cirrhosis: new research provides a basis for rational and targeted treatments. BMJ 2003; 327: 143-147.
9Safadi R, Friedman SL. Hepatic fibrosis--role of hepatic stellate cell activation. MedGenMed 2002; 4: 27.
10Oda M, Yokomori H, Han JY. Regulatory mechanisms of hepatic microcirculation. Clin Hemorheol Microcirc 2003; 29:167-182.
